Anti-CD20 Therapies Show Similar Safety And Efficacy in RRMS & Wheelchair Mishap

Nov 29, 2021, 12:00 AM

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads the news article about how anti-CD20 antibody therapies that target B-cells are highly effective for reducing the risk of relapses in people with RRMS
Also, Price reads “Thanks to a Wheelchair Mishap, I was ‘Busy Goin’ Nowhere’, a column by John Connor.
Are you interested in learning more about multiple sclerosis? If so, please visit:
To join in on conversations regarding multiple sclerosis, please visit: